- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00228436
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
December 19, 2012 updated by: Affymax
A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of Subcutaneously Administered Peginesatide in Chronic Kidney Disease Patients Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis stimulating agent (ESA) treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a Phase 2, dose finding study designed to evaluate peginesatide treatment of participants with CKD not on ESA treatment.
The objective was to determine the range of doses of peginesatide administered subcutaneously once every 4 weeks (Q4W) that increased and maintained hemoglobin at 11 to 13 g/dL.
Study Type
Interventional
Enrollment (Actual)
139
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Białystok, Poland
- Research Facility
-
Gdansk, Poland
- Research Facility
-
Katowice, Poland
- Research Facility
-
Kraków, Poland
- Research Facilities
-
Warszawa, Poland
- Research Facility
-
Łódź, Poland
- Research Facility
-
-
-
-
-
Coventry, United Kingdom
- Research Facility
-
Croydon, United Kingdom
- Research Facility
-
Derby, United Kingdom
- Research Facility
-
Leicester, United Kingdom
- Research Facility
-
London, United Kingdom
- Research Facilities
-
Salford, United Kingdom
- Research Facility
-
Swansea, United Kingdom
- Research Facility
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local and national guidelines;
- Males or females ≥ 18 and ≤ 85 years of age. Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice an adequate form of contraception for at least 4 weeks prior to study start, and must be willing to continue contraception for at least 4 weeks after the last dose of study drug;
- Chronic kidney disease stage 3 or 4 (estimated Glomerular filtration rate [GFR] of 15-60 mL/min within 28 days prior to study drug administration) and not expected to begin dialysis for at least 12 weeks;
- Two hemoglobin values of ≥ 9.0 and < 11.0 g/dL within 14 days prior to study drug administration, including at least one of the values drawn within 7 days prior to study drug administration;
- One serum ferritin level ≥ 100 micrograms per liter (μg/L) and transferrin saturation ≥ 20 % within 4 weeks prior to study drug administration;
- One serum or red cell folate level above lower limit of normal within 4 weeks prior to study drug administration;
- One vitamin B12 level above lower limit of normal within 4 weeks prior to study drug administration;
- Weight ≥ 45 kg within 4 weeks prior to study drug administration;
- One white blood cell count ≥ 3.0 x 10^9/L within 4 weeks prior to study drug administration; and
- One platelet count ≥ 100 x 10^9/L within 4 weeks prior to study drug administration.
Exclusion Criteria:
- Prior treatment with any erythropoiesis stimulating agent in the 12 weeks prior to study drug administration;
- Any prior treatment with Eprex®;
- Known intolerance to any erythropoiesis stimulating agent;
- History of antibodies to any erythropoiesis stimulating agent or history of pure red cell aplasia;
- Prior hemodialysis or peritoneal dialysis treatment;
- Known intolerance to parenteral iron supplementation;
- Red blood cell transfusion within 12 weeks prior to study drug administration;
- Hemoglobinopathy [e.g., homozygous sickle-cell disease (sickle-cell trait does not exclude patient), thalassemia of all types, etc.];
- Known hemolysis;
- Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.);
- C Reactive Protein (CRP) greater than 30 mg/L within the 4 weeks prior to study drug administration;
- Febrile illness within 7 days prior to study drug administration;
- Uncontrolled or symptomatic secondary hyperparathyroidism;
- Poorly controlled hypertension within 4 weeks prior to study drug administration, per Investigator's clinical judgment (e.g. systolic ≥ 170mm Hg, diastolic ≥ 100 mm Hg on repeat readings);
- Epileptic seizure in the 6 months prior to study drug administration;
- Chronic congestive heart failure (New York Heart Association Class IV);
- High likelihood of early withdrawal or interruption of the study;
- Evidence of malignancy within the past 5 years (except non-melanoma skin cancer which is not an exclusion criterion);
- Life expectancy < 12 months;
- Anticipated elective surgery during the study period; and
- Previous exposure to any investigational agent within 6 weeks prior to administration of study drug or planned receipt during the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
|
Other Names:
|
Experimental: Cohort 2
Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
|
Other Names:
|
Experimental: Cohort 3
Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
|
Other Names:
|
Experimental: Cohort 4
Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
|
Other Names:
|
Experimental: Cohort 5
Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
|
Other Names:
|
Experimental: Cohort 6
Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
|
Other Names:
|
Experimental: Cohort 7
Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
|
Other Names:
|
Experimental: Cohort 8
Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants who achieved a target hemoglobin response during the study.
Time Frame: 25 weeks
|
A target hemoglobin response is defined as a hemoglobin increase of ≥ 1.0 gram per deciliter (g/dL) from baseline and a hemoglobin value ≥ 11.0 g/dL during the study.
|
25 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events and serious adverse events
Time Frame: 25 weeks
|
25 weeks
|
Pharmacokinetic parameters
Time Frame: 25 weeks
|
25 weeks
|
Percentage of participants with hemoglobin values in the range of 11.0 to 13.0 g/dL throughout the study.
Time Frame: 25 weeks
|
25 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
November 1, 2007
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
September 27, 2005
First Submitted That Met QC Criteria
September 27, 2005
First Posted (Estimate)
September 29, 2005
Study Record Updates
Last Update Posted (Estimate)
December 21, 2012
Last Update Submitted That Met QC Criteria
December 19, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFX01-04
- 2005-002218-39 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on peginesatide
-
TakedaAffymaxTerminated
-
AffymaxCompletedAnemia | Chronic Kidney Disease | Chronic Renal FailureUnited States
-
AffymaxCompletedAnemia | Chronic Kidney Disease | Chronic Renal FailureBulgaria, Romania, United Kingdom
-
AffymaxTerminatedAnemia | Chronic Kidney Disease | Chronic Renal FailureBulgaria, Romania, Poland, United Kingdom
-
AffymaxTerminatedAnemia | Chronic Kidney Disease | Chronic Renal FailureUnited States
-
AffymaxTerminatedAnemia | Chronic Kidney Disease | Chronic Renal FailureUnited Kingdom
-
AffymaxCompletedCancer | Chemotherapy Induced AnemiaCzech Republic, Poland, United Kingdom
-
AffymaxCompletedCancer | Anemia | Chronic Kidney Disease | Chronic Renal FailureUnited Kingdom
-
AmgenTerminated
-
TakedaCompletedAnemia | Chronic Kidney Disease | Pure Red Cell Aplasia | Chronic Renal FailureUnited Kingdom, France, Germany